Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476)-Reference-Cited by-同舟云学术

Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476)

Published:2022-05-16 Issue:3 Volume:151 Page:422-434
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Intl Journal of Cancer

Author:

James Nicholas D.¹^ORCID,Clarke Noel W.²^ORCID,Cook Adrian³^ORCID,Ali Adnan⁴^ORCID,Hoyle Alex P.⁵,Attard Gerhardt⁶^ORCID,Brawley Christopher D.³^ORCID,Chowdhury Simon⁷,Cross William R.⁸^ORCID,Dearnaley David P.⁹^ORCID,de Bono Johann S.¹^ORCID,Diaz‐Montana Carlos³^ORCID,Gilbert Duncan³^ORCID,Gillessen Silke¹⁰^ORCID,Gilson Clare³¹¹^ORCID,Jones Rob J.¹²^ORCID,Langley Ruth E.³^ORCID,Malik Zafar I.¹³,Matheson David J.¹⁴^ORCID,Millman Robin¹⁵,Parker Chris C.¹⁶,Pugh Cheryl³^ORCID,Rush Hannah³¹⁷^ORCID,Russell J. Martin¹⁸¹⁹,Berthold Dominik R.²⁰^ORCID,Buckner Michelle L.³,Mason Malcolm D.²¹^ORCID,Ritchie Alastair W. S.²²,Birtle Alison J.²³^ORCID,Brock Susannah J.²⁴^ORCID,Das Prantik²⁵^ORCID,Ford Dan²⁶,Gale Joanna²⁷^ORCID,Grant Warren²⁸^ORCID,Gray Emma K.²⁹,Hoskin Peter³⁰^ORCID,Khan Mohammad M.³¹³²,Manetta Caroline³³,McPhail Neil J.³⁴^ORCID,O'Sullivan Joe M.³⁵^ORCID,Parikh Omi³⁶^ORCID,Perna Carla³⁷^ORCID,Pezaro Carmel J.³⁸^ORCID,Protheroe Andrew S.³⁹^ORCID,Robinson Angus J.⁴⁰^ORCID,Rudman Sarah M.¹⁷,Sheehan Denise J.⁴¹,Srihari Narayanan N.⁴²,Syndikus Isabel¹³^ORCID,Tanguay Jacob S.⁴³^ORCID,Thomas Carys W.⁴⁴,Vengalil Salil⁴⁵,Wagstaff John⁴⁶^ORCID,Wylie James P.⁴,Parmar Mahesh K. B.³^ORCID,Sydes Matthew R.³^ORCID,

Affiliation:

1. Institute of Cancer Research London UK

2. The Departments of Surgery & Urology The Christie & Salford Royal Hospitals Manchester UK

3. MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, UCL London UK

4. The Christie NHS Foundation Trust Manchester UK

5. Salford Royal HS Foundation Trust Manchester UK

6. UCL Cancer Institute, University College London London UK

7. Guy's, King's, & St. Thomas' Hospitals, and Sarah Cannon Research Institute London UK

8. St James University Hospital Leeds UK

9. The Institute of Cancer Research and Royal Marsden NHS Foundation Trust London UK

10. Istituto Oncologico della Svizzera Italiana Bellinzona Switzerland

11. Royal Marsden Hospital London UK

12. Beatson West of Scotland Cancer Centre, University of Glasgow Glasgow UK

13. Radiotherapy Unit The Clatterbridge Cancer Centre NHS Foundation Trust Liverpool Liverpool L7 8YA UK

14. School of Allied Health and Midwifery, Faculty of Education, Health and Wellbeing University of Wolverhampton Wolverhampton WS1 3BD UK

15. (PPI) c/o MRC CTU at UCL London UK

16. Uro‐Oncology Unit Royal Marsden Hospital and Institute of Cancer Research Sutton UK

17. Guys and St Thomas' NHS Foundation Trust London UK

18. Institute of Cancer Sciences, University of Glasgow Glasgow UK

19. Beatson West of Scotland Cancer Centre Glasgow UK

20. Centre Hospitalier Universitaire Vaudois (CHUV) Lausanne Switzerland

21. Cardiff University School of Medicine Cardiff UK

22. Gloucestershire Hospitals NHS Foundation Trust Gloucester UK

23. Rosemere Cancer Centre, Lancashire Teaching Hospitals & University of Manchester, University of Central Lancashire Lancashire UK

24. University Hospital Dorset Bournemouth UK

25. Department of Oncology University Hospitals of Derby and Burton NHS Foundation Trust Derby UK

26. City Hospital, Cancer Centre at Queen Elizabeth Hospital Birmingham UK

27. Portsmouth Hospitals University Trust Portsmouth UK

28. Gloucestershire Oncology Centre, Cheltenham General Hospital Cheltenham UK

29. Musgrove Park Hospital Taunton UK

30. Mount Vernon Cancer Centre Northwood UK

31. Department of Oncology Castle Hill Hospital Hull UK

32. Scarborough General Hospital Scarborough UK

33. Brighton and Sussex University Hospitals NHS Trust Brighton UK

34. Department of Clinical Oncology Raigmore Hospital Inverness UK

35. Patrick G Johnston Centre for Cancer Research, Queen's University Belfast Belfast UK

36. Rosemere Cancer Centre, Lancashire Teaching Hospitals NHS Trust Preston UK

37. Royal Surrey NHS Foundation Trust Guildford UK

38. Sheffield Teaching Hospitals NHS Foundation Trust Sheffield UK

39. Oxford University Hospitals NHS Foundation Trust Oxfordshire UK

40. Sussex Cancer Centre Brighton UK

41. Royal Devon & Exeter NHS Foundation Trust Exeter UK

42. Shrewsbury & Telford Hospitals NHS Trust Shrewsbury UK

43. Velindre Cancer Centre Cardiff UK

44. Kent Oncology Centre Maidstone Kent UK

45. University Hospital North Midlands NHS Trust Staffordshire UK

46. Swansea University and the South West UK Cancer Centre Swansea UK

Funder

Astellas Pharma

Cancer Research UK

Janssen Research and Development

Medical Research Council Canada

Novartis

Pfizer

Sanofi

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.34018

Reference16 articles.

1. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer

2. Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study

3. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

4. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

5. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment Intensification With Novel Hormonal Therapy in Castration-Sensitive Prostate Cancer: Patient Identification and Clinical Rationale;Clinical Genitourinary Cancer;2024-12

2. Salvage therapies for biochemical recurrence after definitive local treatment: a systematic review, meta-analysis, and network meta-analysis;Prostate Cancer and Prostatic Diseases;2024-09-13

3. Cardiovascular events among men with prostate cancer treated with androgen receptor signaling inhibitors: a systematic review, meta-analysis, and network meta-analysis;Prostate Cancer and Prostatic Diseases;2024-09-05

4. Metastatic hormone-naïve prostate cancer: a distinct biological entity;Trends in Cancer;2024-09

5. Front-Line Therapeutic Strategy in Metastatic Hormone Sensitive Prostate Cancer: An Updated Therapeutic Algorithm;Clinical Genitourinary Cancer;2024-08